MH is the #1-funded US therapeutic area (~$1.27B/14 deals to start 2026), but the money is going to clinician-augmentation (psychiatry copilots, AI scribes, payer-aligned platforms) and interventional psychiatry (TMS/ketamine/psychedelics) — NOT consumer chatbots. Track which models keep attracting capital vs. the chatbots hitting the regulatory reckoning; watch consolidation (e.g. Spring Health/Alma). Tests whether the market prices in rigor — the evidence-gap thesis.